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Many antiretroviral agents (ARVs) concentrate in genital
secretions. When provided to people with HIV these
agents stop the transmission of the virus, presumably by
i) reducing the concentration of virus and ii) bathing
vulnerable tissues with ARVs during the potential trans-
mission. In 11/13 observational studies ART reduced
HIV transmission. In one observational study that
included gay couples, treatment of the infected partner
stopped transmission. In one randomized controlled
trial (HPTN 052) of 17623 couples at 13 sites in 9 coun-
tries, documented suppression of viremia appears to
have been 100% effective in prevention of HIV transmis-
sion. The maximal potential of ARVs for prevention of
HIV requires universal early or immediate treatment,
with good adherence to therapy. Currently only a few
countries (including the US and Brazil) have guidelines
leading to immediate treatment of infection. In addition,
wider testing is required to identify HIV infected people
who do not know their status. And new tests must be
developed to detect acute HIV infection, a short stage of
disease that contributes disproportionately to the spread
of HIV. Earlier ART benefits the health of the HIV
infected person: CD4 cells are restored to a high level,
tuberculosis is averted, subtle changes in mentation are
avoided, and normal lifespan is restored. While the bio-
medical benefits of early treatment of HIV have been
established, logistical challenges of treatment-including
early treatment-are considerable; and such logistical chal-
lenges compromise more immediate utilization of ARVs.
It can be anticipated that universal immediate ART will
become the standard of care in the near future. Commit-
ment to simplifying treatment regimens and improving
infrastructure is essential. In addition, HIV infected
patients must be inspired to protect their own health
through treatment. Ongoing confusion about when to
start ART among patients and providers convinces
asymptomatic people with HIV infection that delay of
treatment has no adverse consequence, which does not
appear to be the case in either short or long time frames.
While treatment can be difficult, people who are not
offered ARVs are often lost to follow-up. ARVs represent
the cornerstone of combination HIV prevention; optimiz-
ing the clinical and public health benefit(s) of these
agents is of the greatest priority.
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